

Statement of Standalone Audited Financial Results for the Quarter ended 31.03.2019 and Year Ended 31.03.2019
Rs. in lacs

Particulars	Standalone			12 Months	12 Months
	Quarter Ended			Year Ended	Year Ended
	31.03.2019	31.03.2018	31.12.2018	31.03.2019	31.03.2018
	Audited	Audited	Unaudited	Audited	Audited
1 Income from operations					
a Gross Sales/Revenue from Operations	3840.22	3267.31	4189.45	16682.56	12660.42
b Other Operating Income	0.00	0.00	0.00	0.00	0.00
Total Income from operations	3840.22	3267.31	4189.45	16682.56	12660.42
2 Other Income	87.95	13.26	27.86	142.90	45.68
3 Total Income [1+2]	3928.17	3280.57	4217.31	16825.46	12706.10
4 Expenses					
a Cost of materials consumed	746.34	283.68	1290.77	3878.66	2688.60
b Purchases of stock-in-trade	539.39	758.28	399.80	1464.08	3830.84
c. Changes in inventories of finished goods, work in progress and Stock in trade	101.19	84.95	106.07	1941.82	-408.44
d. Excise Duty	0.00	0.00	0.00	0.00	7.13
e. Employee benefits expenses	1059.88	1082.20	1274.04	4661.10	4187.97
f. Finance Cost	27.31	5.28	10.42	74.55	65.72
g. Depreciation and amortisation expense	28.13	1.51	23.06	101.58	31.98
h. Other expenses	1052.23	1181.54	898.72	3803.39	3464.97
Total expenses	3554.47	3397.44	4002.88	15925.18	13868.77
5 Profit before exceptional items and taxes (3-4)	373.70	-116.87	214.43	900.28	-1162.67
6 Exceptional Items	0.00	0.00	0.00	0.00	0.00
7 Profit before tax [5-6]	373.70	-116.87	214.43	900.28	-1162.67
8 Tax expense	76.24	6.08	40.00	178.67	-7.61
9 Net Profit for the period [7-8]	297.46	-122.95	174.43	721.61	-1155.06
10 Other Comprehensive Income					
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
11 Total Other Comprehensive Income [A(i) + A(ii)]	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive Income [9+11]	297.46	-122.95	174.43	721.61	-1155.06
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	1309.90
14 Earnings Per Share (before and after extraordinary items) (of Rs 5/- each)					
a. Basic (Rs.)	1.14	-0.47	0.67	2.75	-4.41
b. Diluted (Rs.)	1.14	-0.47	0.67	2.75	-4.41

(Rs in lakhs)

Statement of Assets and Liabilities		
Particulars	As on 31.03.2019	As on 31.03.2018
ASSETS		
1 Non-current assets		
(a) Property, Plant and Equipment	2161.39	2128.71
(b) Capital Work-in-Progress	189.15	97.92
(c) Goodwill	3.00	3.00
(d) Intangible assets under development	206.27	206.27
(e) Financial assets		
(i) Investments	0.05	0.05
(f) Other non-current assets	1262.72	1084.23
Total non-current assets	3822.58	3520.18
2 Current assets		
(a) Inventories	3269.26	5143.38
(b) Financial assets		
(i) Trade receivables	2075.02	2515.36
(ii) Cash and Cash equivalents	35.70	52.23
(iii) Bank balances other than (ii) above	3817.76	1399.01
(c) Other current assets	558.09	351.32
Total current assets	9755.83	9461.30
TOTAL ASSETS	13578.41	12981.48
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	1309.90	1309.90
(b) Other Equity		
(i) Reserves & Surplus	9137.41	8494.76
Total Equity	10447.31	9804.66
LIABILITIES		
1 Non-current liabilities		
(a) Deferred tax liabilities (Net)	311.91	318.52
(b) Non current borrowings		0.00
Non-current liabilities	311.91	318.52
2 Current Liabilities		
(a) Financial Liabilities		
(i) Trade payables	1186.04	909.26
(ii) Short term borrowings	378.54	830.05
(b) Other current liabilities	559.97	609.63
(c) Provision for tax	694.64	509.36
Total current liabilities	2819.19	2858.30
Total Liabilities	3131.10	3176.82
TOTAL - EQUITY AND LIABILITIES	13578.41	12981.48


Rm



Notes

- 1) The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on May 28, 2018.
- 2) In line with the provisions of Ind AS 18 , the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- 3) Figures for the previous periods have been regrouped , wherever necessary, to correspond with the figures of the current period.
- 4) The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- 5) According to the requirements of Ind AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, revenue for the corresponding Year ended March 31,2018 were reported inclusive of Excise Duty. The Government of India has implemented Goods and Service Tax ("gst") from July 01, 2017 replacing Excise Duty, Service Tax and various indirect taxes. AS per Ind AS 18, the revenue for the Year ended 31-03-2019, is reported net of GST and is not comparable with previous reported year.
- 6) Provision for taxation includes provision for current tax.
- 7) The Board of Directors has proposed a dividend of Rs 0.25 per Equity Shares of Rs 5/- each.
- 8) Figures for the quarter ended 31st March 2019 are balancing figures between the audited figures in respect of full financial year ended 31st March 2019 and published figure upto 3rd quarter ended 31st December 2018.

Place : New Delhi
Date : 28-05-2019



By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Rajpal Singh Kochhar
Managing Director
DIN No 00059492